HCV and the hepatic lipid pathway as a potential treatment target

Margaret Bassendine, David Sheridan, Daniel Felmlee, Simon Bridge, Geoffrey Toms, Robert Dermot Neely

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)
2 Downloads (Pure)

Abstract

Atherosclerosis has been described as a liver disease of the heart. The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus-host interaction is a continuous co-evolutionary process involving the host immune system and viral escape mechanisms. One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: update the hepatologist on lipid metabolism; review the evidence that HCV exploits hepatic lipid pathways to its advantage; discuss approaches to targeting host lipid pathways as adjunctive therapy.
Original languageEnglish
Pages (from-to)1428-40
JournalJournal of Hepatology
Volume55
Issue number6
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Dive into the research topics of 'HCV and the hepatic lipid pathway as a potential treatment target'. Together they form a unique fingerprint.

Cite this